<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004494</url>
  </required_header>
  <id_info>
    <org_study_id>199/14275</org_study_id>
    <secondary_id>SUNY-SB-FDR001488</secondary_id>
    <secondary_id>SUNY-SB-96-077</secondary_id>
    <secondary_id>SUNY-SB-98-2606</secondary_id>
    <secondary_id>FD-R-0001488</secondary_id>
    <nct_id>NCT00004494</nct_id>
  </id_info>
  <brief_title>Phase I Study of Vasoactive Intestinal Peptide in Patients With Acute Respiratory Distress Syndrome and Sepsis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stony Brook University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>State University of New York</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>FDA Office of Orphan Products Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Stony Brook University</source>
  <brief_summary>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine the maximum tolerated dose of vasoactive intestinal peptide in patients with&#xD;
      acute respiratory distress syndrome.&#xD;
&#xD;
      II. Evaluate the safety and pharmacodynamic activity of this peptide in these patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE:&#xD;
&#xD;
      This is a dose escalation study.&#xD;
&#xD;
      Patients receive vasoactive intestinal peptide (VIP) IV over either 6 or 12 hours.&#xD;
&#xD;
      Cohorts of 3 patients each receive escalating doses of VIP over either 6 or 12 hours until&#xD;
      the maximum tolerated dose is determined.&#xD;
&#xD;
      Patients are followed for 30 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 1998</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Sepsis</condition>
  <condition>Respiratory Distress Syndrome</condition>
  <condition>Respiratory Distress Syndrome, Adult</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vasoactive intestinal peptide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:&#xD;
&#xD;
        --Disease Characteristics--&#xD;
&#xD;
        Diagnosis of adult respiratory distress syndrome (ARDS) with sepsis&#xD;
&#xD;
        ARDS characterized by: hypoxemia refractory to supplemental oxygen therapy, diffuse&#xD;
        pulmonary infiltrates, no cardiogenic cause of pulmonary edema, and reduced pulmonary&#xD;
        compliance&#xD;
&#xD;
        Sepsis characterized by: Two or more of the following: Fever or hypothermia; Tachycardia;&#xD;
        Tachypnea; WBC greater than 12,000/mm3 or less than 4,000/mm3 or immature neutrophils;&#xD;
        Hypotension; Clinical suspicion of infection; Inadequate organ perfusion or organ&#xD;
        dysfunction as demonstrated by: Acute deterioration in mental acuity (excluding sedatives&#xD;
        or other nonsepsis causes) OR Unexplained metabolic acidosis OR Oliguria for greater than 2&#xD;
        hours OR Unexplained coagulopathy (elevated PT or PTT or platelet count decreased to less&#xD;
        than 50% of baseline within 24 hours or less than 100,000/mm3) OR Acute elevation of&#xD;
        bilirubin to greater than 2.0 mg/dL AND elevation of alkaline phosphatase, SGOT, or SGPT&#xD;
&#xD;
        No sepsis with unstable BP&#xD;
&#xD;
        --Prior/Concurrent Therapy--&#xD;
&#xD;
        At least 30 days since prior enrollment in investigational trial; No other concurrent&#xD;
        enrollment in investigational trial&#xD;
&#xD;
        --Patient Characteristics--&#xD;
&#xD;
        Hematopoietic: See Disease Characteristics; No uncontrolled hemorrhage (transfusion of 4 or&#xD;
        more units required within past 24 hours); No chemotherapy induced neutropenia (granulocyte&#xD;
        count less than 1000/mm3)&#xD;
&#xD;
        Hepatic: No severe liver disease with portal hypertension&#xD;
&#xD;
        Renal: No anuria (urine output less than 50 mL/day)&#xD;
&#xD;
        Cardiovascular: No cardiogenic shock&#xD;
&#xD;
        Neurologic: No recent stroke, head trauma, or increased intracranial pressure; No other&#xD;
        serious neurologic disorder&#xD;
&#xD;
        Other: Not pregnant; No acquired immune deficiency syndrome; No immunosuppressed transplant&#xD;
        patients; No severe burns; No irreversible underlying condition with rapidly fatal course;&#xD;
        No marked obesity; No recent history of diarrhea&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sami I. Said</last_name>
    <role>Study Chair</role>
    <affiliation>State University of New York</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Veterans Affairs Medical Center - Northport</name>
      <address>
        <city>Northport</city>
        <state>New York</state>
        <zip>11768</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State University of New York Health Sciences Center - Stony Brook</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11790-7775</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2022</verification_date>
  <study_first_submitted>October 18, 1999</study_first_submitted>
  <study_first_submitted_qc>October 18, 1999</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 1999</study_first_posted>
  <last_update_submitted>May 3, 2022</last_update_submitted>
  <last_update_submitted_qc>May 3, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2022</last_update_posted>
  <keyword>cardiovascular and respiratory diseases</keyword>
  <keyword>immunologic disorders and infectious disorders</keyword>
  <keyword>neonatal disorders</keyword>
  <keyword>rare disease</keyword>
  <keyword>respiratory distress syndrome</keyword>
  <keyword>sepsis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vasoactive Intestinal Peptide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

